Abstract: The methods of this invention relate to immunizing animals with conjugates of cytokines and a carrier to induce a prolonged high titre antibody response specific for the cytokine. This invention also relates to the treatment of pathological conditions, e.g., eosinophilia and allograft rejection, associated with the production of cytokines, in particular interleukins, e.g., IL-4, IL-5, IL-9, and IL-13, by immunization with the cytokine conjugates or by administration of antibodies specific for the cytokine. This invention also relates to compositions comprising the cytokine conjugates and the conjugates per se.

Abstract: The invention relates to a combination of (a) an inhibitor of platelet-derived growth factor (PDGF) activity and (b) a vector for vascular endothelial growth factor (VEGF-, especially VEGF-C) gene transfer, a pharmaceutical preparation comprising (a) and (b) in combination together with a pharmaceutically acceptable carrier material; a product comprising (a) and (b) as defined above and optionally a pharmaceutically acceptable carrier material, for simultaneous, chronologically staggered or separate use; a method of administering or the use of said combination or product for the treatment of endothelial damage; and/or to the use of (a) and (b) for the manufacture of said pharmaceutical preparation or product for the treatment of endothelial damage.